As of May 22
| -0.09 / -0.16%|
The 33 analysts offering 12-month price forecasts for Novo Nordisk have a median target of 60.13, with a high estimate of 75.07 and a low estimate of 40.24. The median estimate represents a +4.50% increase from the last price of 57.54.
The current consensus among 34 polled investment analysts is to Buy stock in Novo Nordisk. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.